The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3K

此次收购将通过STX-478扩展礼来的肿瘤学管道，STX-478是分化且可能是同类最佳的突变选择性PI3K

α

啊

inhibitor currently in a Phase 1/2 clinical trial

抑制剂目前正在进行1/2期临床试验

STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's advancements against this disease

STX-478有可能解决30-40%的激素阳性乳腺癌患者，这是基于礼来公司对抗这种疾病的进展

INDIANAPOLIS

印第安纳波利斯

and

和

BOSTON, Mass.

马萨诸塞州波士顿。

,

,

Jan. 13, 2025

2025年1月13日

/PRNewswire/ --

美通社

Eli Lilly and Company

礼来公司

(NYSE: LLY) and

（纽约证券交易所：

Scorpion Therapeutics, Inc.

蝎子治疗公司。

('Scorpion'), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

。STX-478是一种每日一次的口服突变选择性PI3Kα抑制剂，目前正在乳腺癌和其他晚期实体瘤的1/2期临床试验中进行评估。

.

.

STX-478 could represent the next generation of PI3Kα targeting agents by selectively targeting the pathway in cancerous but not healthy cells, thus overcoming a key limitation of currently available medicines that target the PI3Kα pathway. This approach could potentially offer better disease control through deeper pathway inhibition, as well as improved tolerability..

STX-478可以通过选择性靶向癌细胞而非健康细胞中的途径来代表下一代PI3Kα靶向剂，从而克服了目前可用的靶向PI3Kα途径的药物的关键限制。这种方法可能通过更深入的途径抑制以及改善的耐受性来提供更好的疾病控制。。

'PI3Kα mutations occur in a meaningful proportion of hormone-positive breast cancers, and there is significant unmet need for new treatment options that effectively and safely target this pathway,' said

他说：“PI3Kα突变发生在激素阳性乳腺癌中的比例很高，对于有效且安全地靶向该途径的新治疗方案的需求尚未得到满足。”

Jacob Van Naarden

雅各布·范·纳尔登

, executive vice president and president of Lilly Oncology. 'The selectivity profile of STX-478 has led to a differentiated clinical profile, enabling use in combinations with standard-of-care therapies to potentially deliver meaningful impact in earlier treatment settings when there is the best opportunity to improve outcomes for patients.

，礼来肿瘤学执行副总裁兼总裁。”STX-478的选择性特征导致了不同的临床特征，使其与标准护理疗法结合使用，在有最佳机会改善患者预后的早期治疗环境中可能产生有意义的影响。

We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus.'.

我们期待着利用蝎子团队迄今为止的出色工作，以及礼来在乳腺癌方面的深厚专业知识，以更快和更专注的速度进一步推进STX-478。”。

Under the terms of the agreement, Lilly will acquire Scorpion and Scorpion shareholders could receive up to

根据协议条款，礼来将收购Scorpion，Scorpion股东最多可获得

$2.5 billion

25亿美元

in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and sales milestones. Additionally, as part of the transaction, Scorpion will spin out a new entity to hold its employees and non-PI3Kα pipeline assets. The new, independent company would be owned by Scorpion's current shareholders with Lilly holding a minority equity interest.

。此外，作为交易的一部分，Scorpion将分拆出一个新实体，以持有其员工和非PI3Kα管道资产。这家新的独立公司将由Scorpion的现有股东拥有，礼来持有少数股权。

The new company will be led by .

新公司将由领导。

Dr. Friedman

弗里德曼博士

and members of the current Scorpion management team and will focus on discovering and delivering a portfolio of precision medicines to patients, accelerated by Scorpion's discovery capabilities and non-PI3Kα pipeline of medicines.

以及当前Scorpion管理团队的成员，并将专注于发现并向患者提供一系列精准药物，Scorpion的发现能力和非PI3Kα药物管道将加速这一进程。

'Lilly has advanced scientific breakthroughs for some of the most difficult-to-treat cancers,' said

“礼来公司在一些最难治疗的癌症方面取得了科学突破，”他说

Adam Friedman

亚当·弗里德曼

, M.D., Ph.D., president and chief executive officer of Scorpion. 'We believe Lilly's global capabilities and strategic commitment to patients with breast cancer will accelerate our goal of developing STX-478 to improve outcomes for the many patients with solid tumors driven by PI3Kα mutations. This acquisition is a testament to the expertise of the Scorpion team and our drug discovery capabilities, which will become the foundation of our new company.'.

，医学博士，博士，Scorpion总裁兼首席执行官。”我们相信，礼来的全球能力和对乳腺癌患者的战略承诺将加速我们开发STX-478的目标，以改善许多由PI3Kα突变驱动的实体瘤患者的预后。此次收购证明了Scorpion团队的专业知识和我们的药物发现能力，这将成为我们新公司的基础。”。

The transaction is subject to customary closing conditions. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance..

该交易受惯例成交条件的约束。礼来将在交割时根据公认会计原则（GAAP）确定该交易的会计处理。此后，该交易将反映在礼来的财务业绩和财务指南中。。

For Lilly, Citi is acting as exclusive financial advisor and

对于礼来来说，花旗担任独家财务顾问

Ropes & Gray LLP

罗普斯格雷

is acting as legal counsel. For Scorpion,

担任法律顾问。，

Centerview Partners LLC

Centerview Partners LLC

is acting as lead financial advisor with additional financial advisory from Morgan Stanley, and

担任首席财务顾问，并获得摩根士丹利的额外财务顾问，以及

Kirkland & Ellis LLP

凯易国际律师事务所

is acting as legal counsel.

担任法律顾问。

About Scorpion Therapeutics

关于蝎子疗法

Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and fully-integrated discovery capabilities leveraging the most advanced technologies across cancer biology, medicinal chemistry and data sciences.

Scorpion是一家临床阶段的精准肿瘤公司，为癌症患者开发转型靶向治疗。我们利用癌症生物学、药物化学和数据科学领域的最先进技术，建立了专有和完全集成的发现能力。

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Kα program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs. Our focus is on solving current gaps in therapeutic options for patients with cancer by discovering and developing product candidates selective against well-validated, previously undruggable targets to improve patient outcomes..

Scorpion目前的管道由我们的突变选择性PI3Kα程序STX-478领导，由三个内部发现的临床候选产品和多个发现阶段程序组成。我们的重点是通过发现和开发针对经过充分验证的，以前无法治愈的目标的选择性候选产品来改善患者的预后，从而解决目前癌症患者治疗选择方面的差距。。

About Lilly

关于莉莉

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家将科学转化为治疗的医药公司，旨在让世界各地的人们生活得更好。近150年来，我们一直在开创改变生活的发现，今天，我们的药物帮助了全球数以千万计的人。利用生物技术、化学和遗传医学的力量，我们的科学家正在迫切推进新发现，以解决世界上一些最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并减少其最具破坏性的长期影响；推进与阿尔茨海默病的斗争；为一些最令人衰弱的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可控制的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

在迈向更健康世界的每一步中，我们都有一个动机：让数百万人的生活变得更好。这包括提供反映我们世界多样性的创新临床试验，并努力确保我们的药物可获得且负担得起。要了解更多信息，请访问。